BRUSSELS, July 14 (Reuters) – Belgian medical equipment and services company Arseus NV (RCUS.BR) reiterated its outlook for 2010 as an increase in pharmacies buying in raw materials offset falls in its dental business.
Its Fagron drug ingredients unit saw second-quarter sales rise 9.2 percent, benefiting from a trend towards bespoke prescribing by doctors which resulted in pharmacies buying in ingredients to prepare treatments for patients.
This helped offset a fall of 0.9 percent in sales at its dentist equipment unit as surgeries in Belgium and France delayed buying in equipment.
Overall, the company said on Wednesday, it made 108 million euros ($136 million) of sales in the second quarter, compared with a forecast for 107 million in a reuters poll.
Arseus repeated its expectation of sales growth of 5-10 percent in 2010. (Reporting by Ben Deighton; Editing by Dan Lalor) ($1 = 0.7939 euro)